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http://www.molecular-cancer.com/content/12/1/119RESEARCH Open AccessMiR-23a-mediated inhibition of topoisomerase 1
expression potentiates cell response to etoposide
in human hepatocellular carcinoma
Ning Wang1, Meifen Zhu1, Sai-Wah Tsao2, Kwan Man3, Zhangjin Zhang1 and Yibin Feng1*Abstract
Background: microRNAs have been shown to regulate the chemosensitivity of cancer cells. The aim of this study is
to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A)
poison etoposide in human hepatocellular carcinoma (HCC).
Methods: The anti-tumor effect of chemotherapeutic agents in HCC cells were examined in vitro and in vivo
xenograft model. Expression of mRNA and miRNAs were determined by quantitative real-time PCR. Protein
expression was analyzed by immunoblotting.
Results: Overexpression of mir-23a could significantly potentiate the in vitro and in vivo anti-tumor effect of
etoposide; however, ectopic expression of miR-23a fails to sensitize HCC cells to 5-fluorouracil treatment, indicating
the miR-23a-induced cancer cell hypersensitivity in chemotherapy is TOP2A-specific though miR-23a overexpression
could not directly up-regulate TOP2A expression. Topoisomerase 1(TOP1) is down-regulated in miR-23a-overexpressed
HCC cells. MiR-23a could directly bind to 3′untranslated region of TOP1 mRNA, and suppress the corresponding
protein expression and inhibition of miR-23a further arguments the expression of TOP1. MiR-23a was up-regulated
during DNA damage in cancer cells in line with the p53 expression. Up-regulation of p53 induces mir-23a expression,
while suppression of p53 inhibits miR-23a in HCC cells.
Conclusion: Our study sheds light on the role of miR-23a as a potential target in regulating chemosensitivity of HCC cells.
Keywords: miR-23a, Topoisomerase 1, Etoposide, Hepatocellular carcinoma, DNA damageIntroduction
MicroRNAs (miRNAs) are small non-coding RNAs with
an average length of 20–22 nucleotides. Recent studies
have revealed that miRNAs are involved in many different
physiological and pathological processes via regulating
functional genes’ expression [1]. With direct binding to
the 3′-untranslated region (3′-UTR) of these mRNAs, one
individual miRNA could regulate hundreds of genes via
inducing mRNA degradation or prohibiting gene trans-
lation [2,3]. Accumulating evidences have shown that
expression profile of miRNAs differs from that in normal
human tissue [4]. The differential expression of miRNAs* Correspondence: yfeng@hku.hk
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reproduction in any medium, provided the orin consequence regulates oncogenic factors or tumor sup-
pressors, leading to onset/offset of angiogenesis, growth
and metastasis of human cancers [5].
It was further noticed that miRNAs play critical roles
in regulating tumor cell response to chemotherapeutic
agents. Previous studies have shown that the expression
profile of miRNAs in chemoresistant human cancer cell
lines varies from chemo-responsive tumor cells [6]. Altered
expression of miRNAs could control the chemosensitivity
of cancer cells by, either directly regulating apoptosis-
related Bcl-2 family proteins to modify the cellular response
to apoptosis initiated by chemotherapeutic agents, or modu-
lating drug availability to influence responsiveness of tumor
cells indirectly [7]. TOP2A is one of cellular topoisomerases
that determines tumor cell response to chemotherapeutics.
A recent study found that chemosensitivity of tumor cells
could be determined by intracellular topoisomerase level [8],td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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response in cancer therapy. Discovered as a Topoisomerase
2A (TOP2A) poison, etoposide is now a frontline chemo-
therapeutics in treating various human cancers [9]. How-
ever, the mechanism of different responses of tumor cells
to etoposide is not yet clear. A recent study shows that ex-
pression of miRNAs varies in etoposide resistant breast
cancer cells [10], but how miRNAs regulate cell response
upon etoposide remains unclear.
In this study, we report that overexpression of miR-23a
could sensitize HCC to the in vitro and in vivo treatment
of etoposide. MiR-23a fails to boost up response of HCC
cells to 5-fluorouracil (5-Fu) treatment, indicating that
the regulation of miR-23a on response of HCC cell may
be TOP2A poisons-specific. Overexpression of miR-23a
could further impair the cell progression through S phase
when HCC cells were exposed to etoposide, while the
TOP2A expression has not changed. The other topo-
isomerase, TOP1 was suppressed in miR-23a-overxpressed
HCC cells and was validated as the direct target of miR-
23a. Suppression of TOP1 expression by miR-23a results
in reduction of overall intracellular topoisomerase activity
when the cells are exposed to etoposide, which in conse-
quence enhances drug response of HCC cells. Forced
overexpression of miR-23a in HCC cells reduces the
cytotoxicity of TOP1 poison irinotecan, and up-regulation
of miR-23a could be observed in HCC cells upon DNA
damage, during which miR-23a may play a role in the
intracellular TOP1 homeostasis. Furthermore, we found
expression of miR-23a is regulated by p53 in HCC cells.
Our findings shed light on the role of miR-23a as a poten-
tial target in regulating drug responses of HCC cells.Materials and methods
Plasmids and siRNA
The pCMV-MIR Vectors with and without human
miR-23a expression, luciferase expressing-pMir-Target
Vectors with and without TOP1 3′UTR expression were
purchased from Origene (USA). The pRL-CMV Renilla
Luciferase (Ruc) Control Reporter Vectors were obtained
from Promega (USA). The siRNA against human p53 were
from Santa Cruz (USA). The scramble negative control to
miRNAs (scr negative control) and inhibitor against miR-23a
were purchased from Exiqon (Denmark).Cell line and cell culture
The human hepatocellular carcinoma cells HepG2 and
embryonic kidney cell line HEK293T were obtained
from American Type Culture Collection (ATCC, USA).
MHCC97L cell line was kindly gifted by Dr. Man Kwan
from Department of Surgery, The University of Hong Kong
and has been used in our previous published studies
[11,12]. Cells were cultured in High Glucose Dulbecco’sModified Eagle Medium supplemented with 10% Fetal
Bovine Serum and 1% Penicillin/Streptomycin.
Cell viability assays
The cell viability was determined by MTT assay. Briefly,
cells were seeded into 96-well cell culture plate and re-
ceived treatments. 4 h before the end of experiment, 10 μl
of 3- (4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (5 mg/mL) was added and cells were incubated
at 37°C. Then medium was removed and the residue was
dissolved in DMSO. The absorbance of each well was read
at 570 nm with a microplate reader.
Irradiation
Cells were exposed to UV-C irradiation (254 nm) for
10 min then incubated at 37°C, 5% CO2.
Quantitative real-time PCR
Detection of mRNA Total RNA was extracted with Total
RNA purification kit (Norgan, Canada). The Taqman® Gene
Expression Assay (Hs00243257_m1) was conducted for the
detection of TOP1 mRNA transcripts with LigherCycler480
(Roche, USA). GAPDH (Hs02758991_g1) was used as the
loading control. For detection of TOP2A, SYBR Green I
qPCR assay was conducted with primers (left: GCGAGTG
TGCTGGTCACTAA; right: ACAATTGGCCGCTAAAC
TTG). GAPDH was used as the loading control (left:
GAGTCCACTGGCGTCTTCAC; right: TTCACACCCAT
GACGAACAT).
Detection of miRNAs The total RNA containing miRNAs
were extracted with miRNeasy mini Kit (Qiagen, Germany)
under the manufacturer’s instruction. The Taqman®
MicroRNA Assay (000399) was conducted for the de-
tection of mature miR-23a with U6 as loading control
(001973); The Taqman® Pri-miRNA Assay (Hs04270764_pri)
was conducted to detect the expression of pri-miR-23a with
GAPDH as loading control (Hs02758991_g1); For the
detection of pre-miR-23a, SYBR Green I qPCR Assay
was conducted with primers (left: CTGGGGATGGGATTT
GCT; right: TGGAAATCCCTGGCAATG). GAPDH was
used as the loading control (left: GAGTCCACTGGCGTCT
TCAC; right: TTCACACCCATGACGAACAT).
Immunoblotting
Cells were lysed with Radioimmunoprecipitation assay
(RIPA) buffer with complex cocktailed proteinase in-
hibitor (Roche, USA) and phosphatase inhibitor (1 mM
Na3VO4 and 1mM NaF) on ice for 30 minutes followed
by centrifugation at 14,000 rpm at 4°C for 15 minutes.
Supernatants were transferred and protein concentra-
tions were determined by BSA assay (Bio-rad, USA).
Equal yields of protein were separated on SDS-PAGE
and transferred onto a polyvinylidene fluoride mem-
brane (PVDF, Biorad). The membrane was then blocked
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NaCl (150 mmol/L) and Tween 20 (1%) at room temper-
ature for one hour with gentle shaking. The membrane
was then incubated with primary antibodies at 4°C over-
night followed by incubation with appropriate secondary
antibody (Abcam, UK) at room temperature for 1 hour.
The immunoreactivites were detected using ECL ad-
vanced kit (GE Healthcare, UK) and visualized using a
chemiluminenescence imaging system (Bio-Rad, USA).Cell cycle analysis
Cells were seeded in 6-well plate with 50% confluence and
were synchronized by overnight starvation. After treat-
ment the cells were collected and fixed in 75% alcohol for
24 h. Then cell pellet was stained with 50 μg/mL Propidium
iodide (PI) in PBS for 40 min in dark at room temperature.
Cells were washed and resuspended and the cell cycle
distribution was determined with Flow cytometer (BD
FACSCantoII Analyzer, USA). The raw data was col-
lected and analyzed by Flow Jo 7.6 software (USA).Luciferase assay
The HEK293T cells were co-transfected with pMIR
Vectors containing TOP1 3′UTR and miR-23a mimics.
Cells were lysed and the Firefly luciferase activity was
detected and Renilla lucfierase activity was used for
normalization. The lysate was detected with Dual Lucifer-
ase reporter assay kit (Promega, USA) with a luminometer.Xenograft model
The tumor xenograft model was used in this study.
Briefly, 6-week-old female BALB/c nu/nu athymic nude
mice received MHCC97L cells transfected with pCMV
vector injection subcutaneously in 0.2 ml at its left side
of waist and MHCC97L cells with miR-23a overexpression
injection at its right. Mice was then randomized into dif-
ferent groups (n = 5). Etoposide treatment group received
0.2 mL i.p. injection of 7.5 mg/kg etoposide, while 5-Fu
treatment group received the same volume of 25 mg/kg
5-Fu. Control group received the same volume of PBS.
Tumor volume and body weight were measured 3 times
per week for 4 weeks. At the end of the experiment, the
mice were sacrificed with overdose of Phenobarbital
(200 mg/kg) and the tumor was dissected out. All animals
received human care and study protocols complied with
the guidelines of the Laboratory Animal Centre of The
University of Hong Kong and were approved by the
Committee on the Use of Live Animals in Teaching and
Research (CULATR) of the University of Hong Kong.
Moreover, animals were processed according to the
suggested international ethical guidelines for the care
of laboratory animals throughout the experiments.Statistical analysis
Results were analyzed using student T-test and expressed
as mean ± SD.
Results
Overexpression of miR-23a sensitizes tumor cell to
TOP2A poisons
A growing body of studies has focused on the regulation
of cancer cell’s response to chemotherapeutics by miRNAs
[13]. The role of miRNAs in cancer therapy was further
evidenced with the observation that HCC patients with
lower miR-26 level has shorter time of survival but better
response to interferon therapy though miR-26 is highly
expressed in HCC in compared with non-tumor hepatic
tissues [14]. Although it was found the expression of
miR-23a is slightly increased in HCC as evidenced by litera-
ture [15] and our own study (Additional file 1: Figure S1),
we found that overexpression of miR-23a could potenti-
ate the response of HCC to TOP2A poison etoposide
(Figure 1A). This was further evidenced by the fact that
HCC cells with ectopic miR-23a are vulnerable to another
TOP2A poison doxorubicin (Figure 1B). In vivo study
shows that overexpression of miR-23a could promote
the tumor-free survival of the mice upon treatment of
7.5 mg/kg etoposide (Figure 1C). Tumor size was sig-
nificantly reduced by ectopic miR-23a in mice treated
with etoposide (Figure 1D). These findings suggest that
high level of miR-23a may particularly potentiate cellu-
lar response to TOP2A poisons.
TOP2A is responsible for the hypersensitivity of miR-23a-
overxpressing HCC cells to etoposide
As the drug response of miR-23a-overexpressing HCC
cells was potentiated particularly when cells were treated
with TOP2A poisons, we assumed that TOP2A is required
for miR-23a-mediated increased chemosensitivity in HCC
cells. To test this assumption, we treated the HCC cells
with 5-Fu. No significant difference could be observed
between the cytotoxicity of 5-Fu on wild-type or miR-
23a-overexpressing HCC cells (Figure 2A). In vivo study
further confirmed that forced miR-23a expression could
not potentiate the response of HCC xenograft to 5-Fu
(25 mg/kg/2 days). Neither delay on tumorigenesis nor
reduced end-point tumor size could be found in miR-
23-overexpressed xenograft in compared with wild-type
(Figure 2B). These data suggest that the hypersensitivity
mechanism may be TOP2A poisons specific. Previous
studies have shown that the chemosensitivity of TOP2A
poisons could be regulated by the expression level of
TOP2 protein in cancer cells [16]. To further decipher
the role of TOP2A in miR-23a-regulated chemosensitivity
of HCC cells to TOP2A poison, we first confirmed if
the cellular expression of TOP2A has been altered. The
protein expression of TOP2A remains unchanged with
Figure 1 miR-23a enhances cytoxicity of etoposide in human HCC. A shows etoposide exhibits more toxic to HCC cells with ectopic miR-
23a expression. HepG2 and MHCC97L cells with or without expressing ectopic miR-23a were treated with etoposide for 24 and 48 h. Cytotoxicity
was evaluated with MTT assay. Increasing cell death after etoposide treatment was observed in miR-23a-overexpressed HCC cells; B shows
ectopic miR-23a could significantly potentiate HCC cells to doxorubicin treatment. HepG2 and MHCC97L cells with or without expressing ectopic
miR-23a were treated with doxorubicin for 24 and 48 h. Cytotoxicity was evaluated with MTT assay. C shows that miR-23a overexpression
enhances inhibition of HCC tumorigenesis by etoposide. Mice were subcutaneously injected with MHCC97L cells with or without ectopic miR-23a
and treated with etoposide (25 mg/kg/2 days, i.p.). Megascopic xenograft was recorded. Delayed presence of megascopic tumor was observed in
miR-23a-expressed group. D shows that miR-23 overexpression increase tumor response to etoposide. After treatment for 3 weeks, tumor was
dissected out and calculated. Significant reduction on tumor size could be found in miR-23a-expressed group. This picture presents the 3
representatives in each group.
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was significantly suppressed in miR-23a-overexpressed
HCC cells (Figure 2C). Previous study shows that tumor
cells were sensitive to TOP2A poisons without initiating
compensatory expression of TOP2A when TOP1 was
suppressed [8], indicating that increased response to
etoposide may be independent to TOP2A expression.
Cellular response to etoposide when TOP1 was suppressed
by miR-23a may be indicated by the increasing impaired
cell progression through S phase upon etoposide treat-
ment (Figure 2D), and interestingly, cell cycle pro-
gression of wild-type and miR-23a-overexpressed HCC
cells with treatment of 5-Fu have no differences
(Additional file 1: Figure S2) These data suggest that
simultaneous down-regulation of TOP1-mediated en-
hanced response to etoposide may be responsible for
the enhancing sensitivity to TOP2A poison in HCC cells
with miR-23a overexpression.TOP1 is the direct target of miR-23a in hepatocellular
carcinoma
The possible target of miR-23a was predicted with
TargetScan5.2 software, and miR-23a was predicted to
directly bind to the 3′UTR region of human TOP1
mRNA (Figure 3A). Immunoblotting assay confirmed
the inhibition of TOP1 expression by miR-23a (Figure 3B),
which was in line with the mRNA inhibition of TOP1 by
miR-23a (Figure 3C). Suppression of miR-23a by specific
inhibitor restored the mRNA and protein expression of
TOP1 (Figure 3B and C). Significant inhibition of TOP1
mRNA by miR-23a overexpression indicated a post-
transcriptional regulatory mechanism is involved [17].
We then conducted luciferase reporter assay to confirm
the direct binding of miR-23a to the 3′UTR of TOP1
mRNA. With co-transfection of the luciferase reporter
vector encoding 3′UTR of TOP1 mRNA and miR-23a
into HE293T cells, we observed that the luciferase activity
Figure 2 (See legend on next page.)
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Figure 2 miR-23a-induced HCC cell hypersensitivity to 5-Fu treatment requires TOP2A. A shows that miR-23a fails to potentiate HCC cells
to 5-Fu treatment. HepG2 and MHCC97L cells with or without expressing ectopic miR-23a were treated with etoposide for 24 and 48 h.
Cytotoxicity was evaluated with MTT assay. No different cytotoxicity was observed in miR-23a-overexpressed cells in compared with wild-type
cells. B shows that miR-23a could not enhance chemotoxocity of 5-Fu in vivo. Methodologies were described as Figure 1C and D and mice were
treated with 5-Fu (25 mg/kg/2 days, i.p.). Neither delayed presence of megascopic xenograft nor reduced tumor size could be observed in miR-
23a-overexpressed group. This picture presents the 3 representatives in each group. C shows that miR-23a suppresses TOP1 expression without
significantly inducing TOP2A in HCC cells. Wild-type and miR-23a-overexpressed HCC cells were treated with etoposide (20 μM) or 5-Fu (50 μg/mL) for
24 h then protein was collected. The expression of TOP1 and TOP2A was analyzed with immunoblotting. Significant reduction of TOP1 expression in
miR-23a overexpressed HCC cells could be observed. No potent up-regulation of TOP2A could be found. D shows that overexpression of miR-23a
further impaired cell progression through S phase in etoposide-treated HCC cells. Wildtype and miR-23a-overexpressed HCC cells were treated with
etoposide (20 μM) for 24 h and then fixed. Cells were then stained with PI for cell cycle analysis. Accumulation at S phase was observed after
etoposide treatment and ectopic miR-23a enhances this effect of etoposide. *p < 0.05; p < 0.01 in comparison.
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(Figure 3D). These results indicate that TOP1 may be
the direct target of miR-23a.
DNA damage-induced miR-23a regulates TOP1 expression
in hepatoceullar carcinoma cells
The interaction between miR-23a and TOP1 was fur-
ther evidenced in our study by the fact that forced
overexpression of miR-23a significantly reduced the
response of HCC cells with TOP1 poison irinotecan
treatment (Figure 4A). As the content of TOP1 could pre-
dominantly regulate sensitivity of cancer cells in response
to TOP1 poisons, suppression of TOP1 expression by
miR-23a is therefore capable to reduce the content of
TOP1-DNA covalent complex through removing avail-
able TOP1 from the system. Since TOP1 is criticallyFigure 3 TOP1 is the direct target of miR-23a. A shows that the possib
TargetScan software. B shows that TOP1 protein expression was inhibited b
miR-23a-expressing plasmids. Significant suppression of TOP1 protein level
mRNA transcript was inhibited after long exposure to miR-23a. The cells we
plasmids. Potent inhibition of TOP1 mRNA transcripts could be observed in
vector expressing TOP1 3′UTR could be suppressed in the presence of miR
plasmid expressing TOP1 3′UTR and the plasmid expressing miR-23a. The lu
Activity of Renilla Luciferase was expressed as control.required for DNA repair, we examined if miR-23a could
be regulated during DNA damage/repair which may further
evidence the regulation of TOP1 expression by miR-23a.
Interestingly, induced expression of miR-23a in hepatoma
cells could be also observed upon DNA damage induced by
either UV irradiation or hydrogenperoxide treatment
(Figure 4B and Additional file 1: Figure S3), which sug-
gested that miR-23a up-regulation might be the com-
mon feature during DNA damage. Initiation of pri- and
pre-miR-23a expressions in hepatoma cells exposed to
UV irradiation exhibits that miR-23a was transcriptionally
activated upon DNA damage (Figure 4C). In addition, we
observed that the expression of p53, one of the most com-
monly transcription activator of miRNAs, was induced
during DNA damage (Additional file 1: Figure S4), which
was consistent with previsous report [18].le target of TOP1 3′UTR interaction with miR-23a predicted by
y miR-23a. The cells were transiently transfected with either vector of
could be observed in miR-23a-overexpressing cells; C shows that TOP1
re transiently transfected with either vector of miR-23a-expressing
cells with exposure to miR-23a. D shows that the luciferase activity of
-23a. HEK293T cells were co-transfected with luciferase-containing
ciferase activity was detected by dual luciferease reporting assay.
Figure 4 DNA damage-induced miR-23a regulates TOP1 expression. A shows that overexpression of miR-23a attenuates the cytoxicity of
TOP1 poison irinotecan. Wild-type and miR-23a overexpressed HCC cells were treated with irinotecan and cell viability was determined by MTT
assay. B shows that miR-23a was up-regulated upon DNA damage. Cells were exposed to UV-C for 10 min followed by 24 h culture. Total RNA
was collected and miR-23a was detected by RT-qPCR. C shows miR-23a was transcriptionally activated upon DNA damage; RNA was collected
and the pri-miR-23a and pre-miR-23a were detected as described.
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p53 was reported to regulate miRNAs expression through
various mechanisms [19,20]. It was most commonly ob-
served that p53 acts as a positive and negative regulator
of particular miRNA transcription [21,22]. Differential
expression level of miR-23a could be found in the four
HCC cell lines PLC/PRF/5, Hep3B, MHCC97L and HepG2,
and the miR-23a level was correlated with p53 status in
different HCC cell lines (Additional file 1: Figure S5). In
p53-proficient cell lines, high level of miR-23a could be
observed, but ablation miR-23a was found in Hep3B
cells in which p53 is deficient. To further our knowledge
on the regulation of miR-23a expression by p53, the
MDM2 inhibitor nutlin-3α was used to activate p53 in
HepG2 and MHCC97L. In both cell lines the transcription
activity of p53 was induced by nutlin-3α, as evidenced by
the increased expression of p53-downtream target genes
upon nutlin-3α exposure (Additional file 1: Figure S6).
Activation of miR-23a could be observed upon nutlin-
3α treatment in p53-proficient HepG2 and MHCC97L
cells, and it was observed that in p53-dificient Hep3B
cells, nutlin-3α could not influence miR-23a expression
(Figure 5A). The primary transcripts and the precursor
forms of miR-23a were induced, indicating that p53
may transcriptionally up-regulate miR-23a expression
(Figure 5B). Both RNA interference with siRNA against
p53 and presence of inhibitor against p53 pifithrin-α
could abrogate the expression of p53-downstreamedtarget genes (Additional file 1: Figure S7).The expres-
sion of miR-23a was suppressed when p53 is genetically
or pharmacologically inhibited (Figure 5C and Additional
file 1: Figure S8). These findings suggest the p53 is a posi-
tive regulator involved in miR-23a transcription activation.
Discussion
The role of miR-23a in tumor progression is far from
conclusive and still under investigation. Some previous
studies showed that miR-23a could function to promote
tumor progression by inducing tumor cell proliferation
and invasion [3,23]. In our study, we found that expres-
sion of miR-23a may increase in HCC tissue when com-
pared with non-tumor livers, which is consistent with
some previous reports [15]. Mir-23a was showed to regu-
late the glucose metabolism during tumorigenesis via
suppressing gluconeogenesis related genes. High levels
of aerobic glycolysis are therefore induced, which lead
to cancerous transformation of normal cells [15]. More-
over in our study, we found that miR-23a could target
TOP1, which is essential to maintain genomic stability
during DNA damage [24]. Loss of genomic stability once
TOP1 is suppressed may therefore drive cancer develop-
ment. However, as it was found that TOP1/TOP2A
expression in cancer cells are important in determining
the cellular response to chemotherapeutics. It was recently
observed that inhibition of TOP1 level could potentiate
response of tumor cells to doxorubicin treatment without
Figure 5 Expression of miR-23a was control by p53. A shows that induction of p53 by nutlin-3α up-regulates expression of miR-23a. HepG2,
MHCC97L cells (p53-proficient) and Hep3B cells (p53-deficient) were treated with nutlin-3α (20 μM) for 24 h. The miR-23a expression was analyzed by
qRT-PCR. Significant induction of miR-23a expression in HepG2 and MHCC97L but not Hep3B cells could be observed. B shows transcriptional
activation of miR-23a induced by p53. Cells were exposed to nutlin-3α (20 μM) then the pri-miR-23a and pre-miR-23a expressions were analyzed by
RT-qPCR; both primary and precursor form of miR-23a was up-regulated upon nutlin-3α treatment; C shows that suppression of p53 down-regulated
miR-23a. Cells were introduced with RNAi against p53 and significant reduced expression of miR-23a could be observed in cells in which p53
was repressed.
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underlying mechanism remains not clear yet, it was shown
in yeast that overall amount of topoisomerase activity is
necessary for cell survival since more severe deficiencies
of DNA unwinding, cell cycle progression and chromatin
structure could be found in TOP1/TOP2A double mutant
strains in compared to each single mutant [25,26]. It was
therefore suggested that cells are vulnerable if the overallactivity of topoisomerases is below the minimal level
that cell itself sets [8]. Consistently it was observed in
our study that TOP1 down-regulation by miR-23a in
HCC cells could largely potentiate cells to etoposide
and doxorubicin treatment but not 5-Fu exposure, and
forced overexpression of miR-23a in HCC cells reduced
the cytotoxicity of TOP1 poison irinotecan, whose activity
was dominated by the content of endogenous TOP1 level
Figure 6 Overall regulatory mechanism underlying regulation
of chemosensitivity by miR-23a in HCC cells.
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with TOP1 inhibition results in cellular topoisomerase
activity falling below the crucial threshold and trigger-
ing death of the cell. As etoposide is a TOP2A poison
that induce covalent binding of TOP2A protein with
DNA and results in DNA break and fragment in cancer
cells, the etoposide sensitivity may be associated with
the DNA repair mechanism in which the poly (ADP-
ribose)polymerase (PARP) cleavage may be involved.
Indeed, it was found that in etoposide-resistant cancer
cells, deficiency of PARP cleavage was observed upon
etoposide treatment [27]. It is probable that the com-
pensatory activation of PARP cleavage may be initiated
when TOP1 activity has also been suppressed in etoposide-
treated cancer cells since previous study has found PARP
cleavage in cells with TOP1 being inhibited [28]. As
cleavage of PARP eventually results in cancer cell death,
this compensatory action of TOP1 reduction in etoposide-
treated cancer cell may therefore increase the chemother-
apeutic sensitivity.
A previous study has shown that presence of p53
may potentiate cellular response to etoposide treatment
in cancer cells [29]. This may be correlated with p53-
induced miR-23a expression, as it was indicated by our
observation. p53 is well regarded as a tumor suppressive
gene and is of aberrant ablation in human cancer cells.
Inducible DNA damage is able to suppress the intracel-
lular inhibitor of p53, and therefore up-regulates the
p53 expression [30]. This may suggest the involvement
of p53 in DNA damage-induced miR-23a expression in
our observation. Some previous studies have found that
inducing DNA damage by pharmacological approaches
may enhance cellular response to etoposide treatment
[31]. Our findings may advance the knowledge of DNA
damage-induce etoposide sensitivity of cancer cells by
introducing the involvement of miR-23a. Although lit-
erature also reports that high-dose of etoposide treatment
could result in DNA damage [32], we could not observe
potent genotoxic effect of etoposide in our study. HCC
cells were highly resistant to common chemotherapeutics
including etoposide and it is noticed that low dose of
etoposide may not be enough to induce genotoxicity.
However, our study may suggest the DNA damage-
induced miR-23a is responsible for sensitizing HCC cells to
etoposide treatment. Considering that direct overexpression
of miR-23a in tumor cells may promote tumor progression
as reported [33], it may be more practical to trigger miR-
23a expression via inducing DNA damage by genotoxic
agents, which may in consequence potentiate the response
to etoposide treatment. A regimen in combining alkylating
agent cisplatin with etoposide is commonly and tradition-
ally in chemotherapy [34], in this regard, the findings
of our study may add some experimental evidence in the use
and optimization of etoposide-containing chemotherapeuticregimens. The involvement of miR-23a in potentiating
cancer cells to etoposide treatment was shown in Figure 6.
Conclusion
In closing, overexpression of miR-23a potentiates HCC cell
to etoposide-induced cell death. Overexpression of miR-23a
could not synergize 5-Fu-induced cytotoxicity and tumor
inhibition, which indicates the mechanism of hypersen-
sitivity induced by miR-23a is TOP2A poison-specific.
Although TOP2A expression remained unchanged in miR-
23a-overexpressing HCC cells, TOP1 was remarkably down-
regulated, which may lead to the overall topoisomerase
activity fall below the critical threshold for cell survival
when cells are exposed to TOP2A poisons and conse-
quently accelerates cell death. Both mRNA transcripts and
protein expression of TOP1 are suppressed in miR-23a-
overexpressing HCC cells, and luciferase assay shows that
miR-23a may directly bind to the 3′UTR of TOP1 mRNA
to suppress its expression. The interaction between miR-
23a and TOP1 was further evidenced by the fact that forced
overexpression of miR-23a could attenuate the cytotoxicity
of TOP1 poison irinotecan. Activation of miR-23a could be
induced during DNA damage in parallel with up-regulation
of p53 expression. Activation of p53 could increase the
transcripts of pri-, pre- and mature form of miR-23a, while
inhibition of p53 significantly reduced miR-23a level in
p53-proficient HCC cells, indicating that miR-23a may be
transactivated by p53 in HCC cells. Our study shed lights
on the potential of miR-23a as a novel target in regulating
chemosensitivity of cancer cells.
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